Introduction
MET receptor tyrosine kinase activation increases cellular proliferation, survival, mobilization, and invasive capacity (1, 2) . Chronic MET activation in advanced solid tumors occurs via mechanisms including activating MET mutations (3), MET amplification (4), and overexpression of MET or its ligand hepatocyte growth factor (HGF) (5, 6) . Activated MET can drive tumorigenesis (7) and make tumors resistant to epidermal growth factor receptor (EGFR) inhibitors, vascular endothelial growth factor inhibitors, and anti-human EGFR-2 therapies (1) . Tumor MET activity is also associated with aggressive cancer phenotypes (8) and poor prognosis (9, 10) . MET inhibitors may, therefore, have a role in cancer therapy (11, 12) .
Tepotinib is an oral, highly selective and potent MET inhibitor that inhibits MET phosphorylation and downstream signaling. The 50% inhibitory concentration (IC 50 ) of MET was determined as 1.7 nM, and screening against >400 kinases showed high selectivity of tepotinib for MET. Tepotinib inhibits both HGF-dependent and -independent MET kinase activity, providing greater suppression of MET signaling than inhibitors of only ligand-dependent activity (13) . In preclinical studies, tepotinib inhibited the growth of MET-dependent human xenograft tumors and cancer explants (14-17). This phase I first-in-man study was conducted to establish the recommended phase II dose (RP2D) of tepotinib in patients with advanced solid tumors.
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Patients and Methods

Study design and treatment
This open-label, non-randomized, dose-escalation phase I trial in patients with advanced solid tumors (ClinicalTrials.gov ID: NCT01014936) was conducted in compliance with the Declaration of Helsinki, the International Council for Harmonisation Tripartite Guideline for Good Clinical Practice, and all applicable regulatory requirements. The institutional review board for each site approved the study and all patients provided written informed consent to participate.
Dose-escalation used a classic 3+3 design. Patients received one of three tepotinib regimens (R) on a 21-day cycle (Fig. 1A) . Patients were alternately assigned to R1 or R2 until R3 was introduced based on emerging clinical data from the trial, when R1 was discontinued and patients were alternately assigned to R2 or R3. Dose escalation was guided by the occurrence of dose-limiting toxicity (DLT) and grade 2 clinically relevant treatment-emergent adverse events (TEAEs). If no grade ≥2 TEAEs were observed, 100% dose increments were applied; otherwise, lesser increments were applied. Patients received tepotinib until disease progression, unacceptable toxicity, or withdrawal of consent. After dose-escalation, an additional cohort of 12 patients with MET amplification and a cohort of 12 patients with MET overexpression were enrolled at the RP2D. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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The primary objective was to determine the maximum tolerated dose (MTD) of tepotinib for each regimen in patients with solid tumors. Secondary objectives included safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of tepotinib. If it was determined impossible or unnecessary to establish an MTD in a given regimen, an RP2D would be established.
Patients
Patients had measurable or evaluable solid tumors, either refractory to standard therapy or for which no effective standard therapy was available, Eastern Cooperative Oncology Group performance status 0-2, and adequate hematological, liver and renal function. MET status was not used for initial recruitment, while patients in the RP2D expansion cohort (R3) required either MET amplification or MET overexpression. Patients who had received systemic anticancer therapy within 28 days of trial treatment or prior radiotherapy to >30% of bone marrow were ineligible. See Supplementary Information for full inclusion and exclusion criteria.
Assessments
Patients were monitored for toxicity throughout the trial. TEAEs were graded using the National Cancer Institute's Common Terminology Criteria for Adverse non-hematological TEAE (except nausea and vomiting with no adequate treatment, and alopecia); grade ≥3 liver event requiring >7 days recovery to baseline or to grade ≤1 for patients without liver metastases or to grade ≤2 for those with metastases; grade ≥3 lipase and/or amylase rise with pancreatitis confirmation; or any other event that caused a delay of >21 days in planned tepotinib administration due to prolonged recovery to grade ≤1 or baseline status. TEAEs assessed by the investigator to be exclusively related to the patient's underlying disease or medical condition were not considered DLTs. The MTD was defined as the dose level below that at which two of three patients or two of six patients (depending on the size of the cohort) experienced a DLT.
Tumors were assessed at baseline and the end of every second cycle by radiography, computed tomography, or magnetic resonance imaging. Tumor response assessments were based on Response Evaluation Criteria in Solid Tumors version 1.0; best overall response (BOR) was assessed between baseline and disease progression. Partial (PR) and complete responses were confirmed 6 weeks after first evaluation.
Pharmacokinetics
Blood samples were taken for PK analysis during cycle 1 (R1 and R3: up to 24 hours post-dose days 1 and 14, and pre-dose days 3, 8, and 17; R2: up to 48 hours post-dose days 1 and 19 and pre-dose days 3 and 8 of tepotinib were explored in R1 and R2 patient subsets. The bioavailability of capsule and tablet formulations was compared for tepotinib 500 mg dosing.
Differences in area under the plasma concentration curve (AUC) and observed maximum plasma concentration (C max ) between groups (fed vs. fasted, tablet vs. capsule) were assessed using analysis of variance (ANOVA) and differences in time to reach the maximum plasma concentration (t max ) by computing the Hodges-Lehmann shift estimate. Dose proportionality was assessed using ANOVA.
Human PK profiles, including 2914 data points from 419 patients who received tepotinib 30-1400 mg orally once daily, were analyzed with compartmental models using a population approach. The population PK model characterized both the doseplasma concentration relationship of tepotinib after oral administration in humans, and the associated PK variability between individuals and the intrinsic/extrinsic factors predictive of such variability. Further details on population PK modeling are included in the Supplementary Information.
Biomarkers
Paired tumor biopsies for MET status and PD biomarker assessment were performed when possible and were required from all patients recruited after October 15, 2010 unless archived tumor samples were available. The first biopsy was taken during screening, and the second between days 9 and 14 of cycle 1 (R1), or days 17 MET amplification was also determined by a next-generation sequencing-based method (Foundation Medicine, Cambridge, USA) on either archived or fresh pretreatment tumor biopsies.
Statistical plan
Statistical determination of sample size was unnecessary as the protocol followed a classic 3+3 design. The primary endpoint was the incidence of DLTs occurring during the first treatment cycle and treatment-related TEAEs. Summary statistics (means, medians, ranges, and appropriate measures of variability) were calculated for each dose level. Secondary endpoints included safety, tolerability, PK, PD, and antitumor activity. All statistical analyses are regarded as exploratory.
Model-informed selection of the recommended Phase II dose
Preclinical PK/PD model simulations were performed to evaluate the correlation between target inhibition and tumor growth inhibition (TGI) as measured by the The KP-4 human pancreatic ductal cell carcinoma cell line (RCB1005; Riken Cell Bank, Japan) was used to generate xenografts in BALB/c-nu/nu mice because it is considered representative of human tumors with MET pathway activation and sensitivity to MET inhibitors. Xenograft tumors were generated as previously reported (15) . All animal studies were conducted at Merck KGaA, Darmstadt, Germany, in compliance with the institutional ethical guidelines. Tepotinib was produced at Merck KGaA, Darmstadt, Germany, and prepared for oral administration, as previously described (18) . The effect of tepotinib on KP-4 xenograft-bearing mice was determined in a short-term (1-4 day) PK/PD study and longer-term (10-16 day) efficacy studies. In the preclinical PK/PD study, target inhibition was assessed according to phospho-MET modulation in xenograft tumors; in TGI studies, tumor size was measured. Longitudinal PK and PD measurements from KP-4 tumor-bearing mice in these studies, and clinical PD assessments based on paired biopsies (pre-and on-treatment) from patients in the first-in-man study (NCT01014936) were then integrated into mathematical models. This translational modeling approach enabled the prediction of an effective dose in humans, targeting a phospho-MET level that was relevant for preclinical efficacy. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Results
Patient characteristics and disposition
Overall, 203 patients were screened at four sites: MD Anderson Cancer Center, R2 (range 1.0-27.6 weeks), and 62 patients on R3 (range 0.7-94.9 weeks). In the 500 mg cohort, the median time on treatment was 6.0 weeks (range 0.7-42.4 weeks). Full details of time on treatment for all dose cohorts are shown in Supplementary Table S1 . (11, 26 .2%), fatigue (9, 21.4%) and decreased appetite (7, 16 .7%) ( Supplementary Table S2 ). Of the patients receiving tepotinib 500 mg, six (14.3%) and nine (21.4%) temporarily or permanently discontinued treatment due to TEAEs, respectively. Two (4.8%) patients in the 500 mg cohort had their dose reduced.
Safety
Overall, 53 (35.6%) patients reported serious adverse events (SAEs). In one patient these were considered related to study treatment (grade 3 nausea and grade 3 vomiting, R2). The most frequent SAEs in R3 were grade 2 or 3 gastrointestinal disorders. One patient (R3, tepotinib 500 mg once daily) died due to an SAE of hepatic failure recorded as disease progression unrelated to the study drug.
Pharmacokinetics
In fasting patients, the initial capsule formulation produced highly variable AUC and C max , so the formulation was optimized and administered with food. The following PK results were obtained in fed patients using the optimized formulation, including the 500 mg tablet formulation (see Supplementary Data, Tables S3, S4 , S5, and S6). Tepotinib was absorbed slowly after the first dose, with a median t max of 8-10 hours. Increases in C max and AUC 0-24h with increasing dose were observed after single and multiple dosing for both once daily and 3 x/week tepotinib administration. A dose-proportional increase in C max and AUC 0-24h occurred for oncedaily doses ≤300 mg, with less than dose-proportional increases at higher doses. Based on the median AUC 0-24h accumulation ratio of 3.3 after multiple once-daily dosing (500 mg tablet formulation), the average effective t 1/2 was estimated to be approximately 46 hours. Correspondingly small peak-to-trough fluctuations were observed at steady state, eg, patients receiving tepotinib 500 mg in tablet form exhibited fluctuations of 32.1% around the geometric mean C av of 1097.9 ng/mL ( Supplementary Table S4 and Supplementary Fig. S2 ).
Steady-state exposure to tepotinib was increased for patients receiving 500 mg tepotinib as tablets vs. capsules, with geometric mean AUC 0-24h and C max higher by 37% and 38%, respectively. t max was unaffected by formulation as assessed after the first dose.
Clinical antitumor activity of tepotinib
The BOR in R3 was PR in two patients (Table 3) Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Targeted pharmacokinetics and pharmacodynamic threshold
In the preclinical efficacy studies, tumor control was observed in treatment groups receiving a daily dose of tepotinib ≥25 mg/kg ( Fig. 2A) . The Simeoni tumor growth model was found to adequately fit the treatment effects of tepotinib.
Concentrations of tepotinib required to achieve 90% (EC 90 ) to 95% (EC 95 ) maximum tumor inhibition were estimated to be within the range 390-823 ng/mL in humans after correcting for protein binding differences (2.9% in mice and 1.6% in humans).
The correlation plot of efficacy reflected by TGI vs. target modulation modelpredicted average phospho-MET inhibition suggested that regression in KP-4
xenograft tumors corresponded to approximately 95% phospho-MET inhibition (Fig.   2B ). Therefore, a PD criterion of sustained nearly complete inhibition of phospho-MET (greater than 95%) was introduced as the targeted PD threshold in phase II development.
Clinical dose selection
Population PD simulation was performed using the full inhibitory turnover I max PD model driven by the concentrations simulated from the population PK model, including estimated PK and PD variability. Targeting the PD criterion of sustained close-to-complete (≥95%) phospho-MET inhibition in tumors, simulations suggested that a regimen of tepotinib 500 mg once daily could achieve the PD threshold in 90% of the population (Fig. 2C) . The clinical PK data on day 14 show that at a tepotinib dose of 500 mg once daily in humans, the individual trough tepotinib concentrations were within or above the target range and the mean steady-state concentration is Supplementary Fig. S2 ).
Both PK and PD evidence supported the selection of tepotinib 500 mg once daily as the RP2D, which was well tolerated in the first-in-man trial and expected to deliver clinical efficacy in the target population. Further results from the modeling of preclinical and human data are presented in Supplementary Fig. S4 and Supplementary Table S7 . 
Discussion
This first-in-man study was conducted to establish the MTD of tepotinib in patients with advanced solid tumors, using a classic 3+3 dose-escalation design. We analyzed data from 149 patients treated according to three dose-escalation regimens (R1-3). Tepotinib treatment was well-tolerated up to 1400 mg but no MTD could be defined. We have used a translational modeling approach to establish the tepotinib required to achieve tumor regression. Targeting this PD threshold, a biologically active dose of 500 mg once daily was proposed as the RP2D for tepotinib in patients with solid tumors. In addition, continuous daily dosing with 500 mg of tepotinib was predicted to achieve the target exposure range (390-823 ng/mL). This dose is predicted to achieve continuous ≥95% MET inhibition in 90% of the population.
Steady-state concentration time profiles at the 500 mg dose level, both for the capsule and the tablet formulation, showed exposure beyond the threshold as shown in Supplementary Fig. S2, and Among the several types of MET inhibitors in development, potent, selective MET inhibitors are most likely to deliver optimal inhibition of MET with an optimal benefitrisk ratio. The potency of tepotinib reduces its effective dose, and its selectivity minimizes the risk of toxicity due to off-target kinase inhibition, increasing its therapeutic margin. The main TEAEs associated with tepotinib were grade 1 or 2 peripheral edema, fatigue, decreased appetite, and nausea and vomiting. Some (20, 21) . While the incidence of grade ≥3 treatment-related TEAEs was highest in the cohort that received continuous daily tepotinib (R3), tepotinib was well-tolerated at the RP2D of 500 mg once daily with no DLTs and only two treatment-related TEAEs leading to discontinuation. The PK characteristics of tepotinib allow oral once-daily dosing, which assists compliance, and its long half-life ensures a small peak-trough variation over 24 hours, reducing the risk of toxicity at peak and suboptimal inhibition at trough. These PK characteristics also support steady target inhibition, and in conjunction with available safety and tolerability results, constitute a promising drug profile for tepotinib.
Although preclinical studies suggested that MET alterations, either overexpression or more especially genetic alterations such as MET amplification, may trigger a tumor to become more sensitive to MET inhibitors (1), the majority of patients in this study were not selected according to MET status. This non-selected recruitment to the trial was primarily designed to investigate safety, tolerability, PK, and PD; nevertheless, antitumor activity was observed. The BOR was a PR in two (22) (23) (24) (25) . A pooled safety analysis of 260 patients who received tepotinib 500 mg in five phase Ib/II studies also showed the 500 mg dose to be generally well tolerated (26) . In patients with MET-amplified EGFRmutant NSCLC with resistance to EGFR tyrosine kinase inhibitors, treatment with tepotinib plus gefitinib greatly improved outcomes vs. the chemotherapy control arm Interim data from an ongoing study of patients with NSCLC harboring MET exon 14skipping alterations reported an overall response rate of 45% to 55% (27) .
In summary, the RP2D of 500 mg tepotinib orally once daily is well-tolerated by patients with advanced solid tumors. This first-in-man trial also demonstrated that tepotinib can be administered safely up to 1400 mg/day. Patients with high-level MET-expressing tumors appear to benefit most from treatment, and additional clinical studies in patients with MET dysregulated tumors are ongoing.
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